Well... that aged poorly: Aged Care Industry Spotlight

Good morning,

Welcome to today's edition of The Armchair Analyst, a 5-minute daily update on the ASX life-sciences sector.

For this edition of my Biotech 165 challenge, I’m doing a spotlight on the aged care sector.

Not sexy.

A slow-moving beast that still has so much legacy… 

But change is needed.

Not for efficiency, but compliance.

A silver tsunami is coming with Australia's aging population, and we are not ready.

That was the frank outcome from the multi-year Royal Commission into aged care. 

23 public hearings. 641 witnesses. 10,500+ submissions.

The technology is still stuck in the past.

The “button on a wall” nurse call product still dominates the market, but this is not enough to cover the additional liabilities, care minutes, reporting and resident tracking.

Only technology can solve that.

There are three companies I am going to take a look at today.

First, the incumbent.

Austco Healthcare (ASX: AHC) is a $125 million capped, defensible business with $80M+ in revenue, predominantly from its nurse call product.

Next, the innovators.

InteliCare (ASX: ICR) and Talius Group (ASX: TAL) - two sub $25M microcaps building the technology infrastructure to save the aged care industry.

Big institutions are generally slow to adopt new technology.

If it ain't broke, don't fix it.

But even if it is broken, it can be easier to work with a system you know rather than to go through the pain of implementing something entirely new.

This is the classic story of the technology adoption curve.

A small part of the market, the early adopters, maybe 20%, will catch on first. But once it reaches the mainstream market, selling software gets hard.

The software has to be a clear solution to an obvious, unsolved problem.

OR, there has to be external pressure that forces organisations to make a change.

For the aged care sector… that external pressure is here.

It started in 2017 with a man named Bob Spriggs.

The ABC ran a story about an elderly South Australian given ten times his prescribed dose of medication at the Oakden facility in Adelaide.

Following this story, Four Corners aired Who Cares, a two-part investigation into neglect and malnutrition in the aged care sector. 

Within ten days, the Australian Prime Minister at the time, Scott Morrison, announced a Royal Commission into Aged Care in Australia.

23 public hearings. 641 witnesses. 10,500+ submissions.

The sector was in the spotlight, with the interim report titled "Neglect" tabled in October 2019.

The final report, Care, Dignity and Respect, was completed in Febuary 2021 with 148 recommendations. (Final Report)

Over the next few years, the recommendations from the report started to flow through into legislation:

If you run a residential aged care facility in 2026, the operational reality is that you MUST now provide the required care minutes, record them, and have a registered nurse on-site 24/7.

In a sector with a chronic nursing shortage, boards of aged care facilities are facing registration suspensions, fines, and liabilities if they fall short.

THIS is the exact type of external pressure that closes the chasm across the technology adoption curve in a sector that is extremely slow to move.

There are a number of different technologies that help to make an aged care facility operate:

(There are a few other bits and pieces, workforce management, CCTV, Wi-Fi access, but these aren't specific to the aged care sector.)

While most aged care facilities will have a bunch of these systems, very few have the technology infrastructure to tie them all together.

This means a lot of manual work to track residence and implement the new compliance policies. 

Most aged care facilities are still stuck with their hero product, nurse call.

Essentially a “button in the wall”.

This has been a very lucrative product for the incumbent in the industry, the A$125 million-capped Austco Healthcare (ASX: AHC).

But a nurse call system is no longer sufficient to cover liability in aged care facilities, as care minutes and increased reporting are starting to weigh on the sector.

So the industry is looking for better solutions.

Not because they want to improve their processes…

But because they have to.

There is a silver tsunami coming, and aged care facilities are under the pump to fix their digital infrastructure to keep up.

Founded in 1986, Austco is THE nurse call player.

Globally deployed across 4,500+ sites in 60+ countries, with the nurse call platform installed in just about every hospital you've been admitted to in the last decade. 

The numbers?

Market cap $125M. FY25 revenue $81.4M. EBITDA $13M. Debt-free. $14.5M cash.

But it still trades like a stale industrial stock on less than 1.5x revenue… 

Because it is not a scalable growth play.

88% of its revenue comes from hardware sales.

Every dollar of this revenue requires Austco to find a new building, win the tender, ship the gear, install it, and walk away. They have to do it again next year in a different building to grow.

Here’s the challenge for Austco…

A focus on software cannibalises its own business.

It’s the classic innovator's dilemma.

They’ve built an $80M+ revenue business off the back of nurse call, so why change?

The CEO has been there since 2015. The shareholders are happy with the cash flow and expanding margins. 

If it ain't broke, don’t fix it.

So instead of investing in innovation, they're running the roll-up playbook. 

Three acquisitions in two years - Teknocorp, Amentco, G&S Technologies. All Austco's own resellers. 

Buying the channel, not building the platform.

Defence, not offence.

It's also exactly what an incumbent does when it's protecting its installed base instead of building the next product.

But if Austco doesn’t focus on the software side, the monopoly it has historically enjoyed will start to unravel.

The industry is moving towards tracking, compliance and technology.

A button on the wall just won’t cut it anymore.

Austco's response is a technology platform called Tacera Pulse… but it comes bundled, and you’re locked in to Austco’s ecosystem.

The other software providers that I’ll talk about today (two smaller players on the ASX) are device-agnostic.

This makes them scalable across other providers that are not locked into Austco.

The software will be the differentiator. And the industry is moving in that direction.

There are two ASX-listed healthcare companies that I want to talk about today, both of which are moving quickly to capture the fertile ground in the aged care market. 

Both with new CEOs, both are ready to ride the tailwinds of the $5.6 billion aged care reform package.

InteliCare (ASX: ICR) and Talius Group (ASX: TAL).

Market Cap: $15M

Cash Balance: ~$500K

Revenues: Small historical revenue, with the breakthrough being a recently signed $8.8M, 5-year deal with mecwacare.

Last month, Intelicare signed an $8.8 million deal with mecwacare, Victoria’s third-largest aged care facility:

This deal solidified the relationship established during the pilot trial the company commenced last year.

I was fortunate enough to visit the mecwacare facility last week and meet David, the facility manager.

InteliCare’s product was built in collaboration with mecwacare.

It’s not just a replacement for nurse call… it is a holistic change in how the entire facility operates.

Equipment tracking, fall detection, patient monitoring, sleep analytics, predictive deterioration alerts.

A digital backbone.

All of these things work together to improve patient care, remove the administrative burden and help the facility build trust with families.

This digital transformation is disruptive.

In the true sense of the word - but mostly in a good way.

It also means convincing aged care facilities to roll out this technology is challenging.

Sales cycles are long. Many stakeholders are involved in the decision. It's the type of decision that works top-down, not bottom-up.

The bull case for InteliCare is that it signs on a few more customers like mecwacare - locking in large amounts of contracted revenue and providing predictable cash flows for the business.

The challenge in getting there is that its balance sheet is thin (with just $500k in the bank).

When you're asking a $1B aged care provider to bet on a $15M micro-cap, the bank balance question gets asked very early in the meeting.

The other challenge for InteliCare is customer concentration risk.

On a forward-looking basis, mecwacare is 95% of its current revenues. 

The platform was designed in collaboration with mecwacare and they have had a big sway over its features and design.

InteliCare will need to diversify its revenue base to avoid falling into the trap of becoming a one-customer business.

That said, large seven-figure deals are hard to ignore. 

Well done to the InteliCare team for closing this one.

Angus Cameron stepped into the CEO role in March 2026.

30 years in healthcare, most recently Regional Business Leader, Transformation & Solutions at Philips Healthcare USA (a US$9B revenue division). 

Before Philips, senior leadership at EY, KPMG, and Cardinal Health.

His specialty? 

Healthcare business transformations, turning around underperforming healthcare divisions, scaling commercial operations, and driving digital adoption inside complex health systems.

His mandate from the Board is explicit…

Drive the mecwacare rollout, expand into other residential aged care networks, and push into retirement villages.

Market Cap: $25M

Cash Balance: ~$5M

Revenues: $7.66 million in FY2025. $3.3 million of that is ARR.

Talius is a bit more established than InteliCare and has a $3.3 million recurring revenue floor from software sales.

Its software integrates with multiple devices, nurse call systems, third-party pendants, environmental sensors, and the major clinical care management software platforms.

You can see a demo of the product here at 39:25:

It’s not my place to comment on the quality of the different platforms between Talius and InteliCare’s software… 

(That’s one for the aged care providers themselves to assess).

But what I can comment on is the sales strategy…

Talius has ~51,000 active subscriptions (each tied to a device on the platform), anchored by enterprise providers such as Bolton Clarke, Uniting, Keyton, and Silverchain. 

(A mix of home care, retirement living and residential aged care).

For smaller deals, Talius leverages its channel relationships.

Partners like Wesco walk into the facility, sell their bundled solution, and Talius rides underneath as the platform layer.

Also, New Zealand's national ambulance service plugged Talius in behind their existing pendant base.

For larger deals, this is where Talius is going direct.

Land and expand.

While InteliCare has one large customer, Talius has a bunch of smaller customers.

Albeit with more established revenue and a healthier balance sheet.

The step change for Talius will be when it secures those large seven-figure deals that investors love and move the needle.

The catalyst deals.

Pat Howard stepped into the Talius CEO role in February 2026. 

From 2019 to 2023, Pat was CEO of ASX-listed MSL Solutions (ASX: MSL), a SaaS provider of point-of-sale systems for hospitality and stadiums across 47 countries.

He took MSL from a sub-$20M microcap to a sale exit at $119 million within four years:

He has a track record of turning around organisations… most famously, he was the Team Performance Manager at Cricket Australia during the “SandpaperGate” scandal. 

(It’s an amazing story if you ever get the chance to meet Pat in person)

Pat has a competitive tilt, which I like in an organisation leader…

But most importantly, Pat has a proven track record in growing microcap companies and returning value to shareholders.

What I liked about both Talius and InteliCare is that they are hungry organisations eager to grow.

Each new CEO puffed out their chest when I told them my idea for this article, and both boldly said… “We’ll go head-to-head”.

Competition is good, and I suspect it will drive both companies to become successful.

Because the reality is… this market opportunity is huge.

… and the tailwinds are blowing.

Right now, less than 5% of aged care facilities in Australia have adopted digital platform services.

It's still all nurse call. Buttons on a wall.

But it all comes back to the technology adoption curve and the uncomfortable question… 

What will actually unlock this opportunity and close the chasm between the early market and the mainstream?

It's this…

Aged care facilities were raked through the coals over the last five years.

Now it's time to implement everything they've learned.

While Austco rolls up and defends its position, these two small caps are pushing each other forward to outdo a 40-year monopoly.

Aged care isn't a sexy business like Artificial Intelligence or GLP-1 drug development.

But it's one where the winners will be there for a LONG time.

Get your foot in the door, and keep it there.

See you all tomorrow,

The Armchair Analyst.

Arovella Therapeutics (ASX: ALA) announces the resignation of CEO Dr Michael Baker, alongside three directors, as the board undergoes a major refresh. (ALA)

🪑 Just when you think that it’s over, the saga continues. Another 249D. 

FOUR board members out. 

The three board members from the original 249D are all in.

(Bit of a governance disaster when all three board members have been nominated and represent one shareholder… )

Entropy Neurodynamics (ASX: ENP) reports a 75% response rate among patients (n=12) with treatment-resistant irritable bowel syndrome from its oral psilocibin product. Next will be a larger trial with its IV-based psilocin product. (ENP)

🪑 Genuinely a good result in a small clinical trial. 

I know a few people with IBS and gut issues where traditional methods of remedy haven’t worked at all. This could be a solution.

Nexsen Limited (ASX: NXN) announces a partnership with Universiti Malaya to launch a Joint Research Facility to develop a rapid dual-sensor biosensor for detecting foodborne pathogens. (NXN)

AdAlta (ASX: 1AD) announces a A$2.5M strategic placement to advance its Chinese-licensed CAR-T cell therapy. (1AD)

Imricor Medical Systems (ASX: IMR) completes a strongly supported A$60M capital raise at A$1.85 per share. (IMR)

Cynata Therapeutics (ASX: CYP) secures $1.5M via a placement at $0.25 per share. (CYP)

🪑 Interesting deal on the eve of the clinical trial results. 

A clearer signal to the market that it wants to shore up the balance sheet without blowing out the cap structure in case of a positive readout.

What I found most interesting about this one is that CYP has the ATM facility sitting there… strange to do such a small cap raise without just tapping that one.